<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00808834</url>
  </required_header>
  <id_info>
    <org_study_id>P-335-C-008</org_study_id>
    <nct_id>NCT00808834</nct_id>
  </id_info>
  <brief_title>Non-dispense Comfort Comparison of Two Silicone Hydrogel Lenses</brief_title>
  <official_title>Non-dispense Comfort Comparison of Two Silicone Hydrogel Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CIBA VISION</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare subjective responses to two contact lenses after 15
      minutes of wear.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comfort After Insertion</measure>
    <time_frame>30-60 seconds after initial insertion</time_frame>
    <description>Evaluated by the subject and measured on a 10-point scale, with 1 being poor and 10 being excellent.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">196</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Senofilcon A / Lotrafilcon A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Senofilcon A, followed by Lotrafilcon A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lotrafilcon A / Senofilcon A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Lotrafilcon A, followed by Senofilcon A</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lotrafilcon A contact lens</intervention_name>
    <description>Investigational, silicone hydrogel, spherical, soft contact lens</description>
    <arm_group_label>Senofilcon A / Lotrafilcon A</arm_group_label>
    <arm_group_label>Lotrafilcon A / Senofilcon A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Senofilcon A contact lens</intervention_name>
    <description>Commercially marketed, silicone hydrogel, spherical, soft contact lens</description>
    <arm_group_label>Senofilcon A / Lotrafilcon A</arm_group_label>
    <arm_group_label>Lotrafilcon A / Senofilcon A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Currently wearing soft contact lenses

          -  Replaces lenses on a weekly or longer schedule

          -  Other protocol-defined inclusion/exclusion criteria may apply

        Exclusion Criteria:

          -  Requires concurrent ocular medication

          -  Eye injury or surgery within twelve weeks immediately prior to enrollment

          -  Currently wearing soft toric lens wearers

          -  Those who dispose of their soft lenses on a daily basis

          -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2008</study_first_submitted>
  <study_first_submitted_qc>December 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2008</study_first_posted>
  <results_first_submitted>June 18, 2010</results_first_submitted>
  <results_first_submitted_qc>September 16, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 4, 2010</results_first_posted>
  <last_update_submitted>June 26, 2012</last_update_submitted>
  <last_update_submitted_qc>June 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Senofilcon A / Lotrafilcon A</title>
          <description>Senofilcon A, followed by Lotrafilcon A</description>
        </group>
        <group group_id="P2">
          <title>Lotrafilcon A / Senofilcon A</title>
          <description>Lotrafilcon A, followed by Senofilcon A</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall</title>
          <description>This reporting group includes all enrolled and exposed subjects.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="196"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.7" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comfort After Insertion</title>
        <description>Evaluated by the subject and measured on a 10-point scale, with 1 being poor and 10 being excellent.</description>
        <time_frame>30-60 seconds after initial insertion</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A</title>
            <description>Commercially marketed, silicone hydrogel, spherical, soft contact lens</description>
          </group>
          <group group_id="O2">
            <title>Lotrafilcon A</title>
            <description>Investigational, silicone hydrogel, spherical, soft contact lens</description>
          </group>
        </group_list>
        <measure>
          <title>Comfort After Insertion</title>
          <description>Evaluated by the subject and measured on a 10-point scale, with 1 being poor and 10 being excellent.</description>
          <population>Per protocol</population>
          <units>Scale 1-10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="1.5"/>
                    <measurement group_id="O2" value="7.7" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days, duration of the trial.</time_frame>
      <desc>Subjects wore 2 pairs of contact lenses, 15 minutes per pair.</desc>
      <group_list>
        <group group_id="E1">
          <title>Senofilcon A</title>
          <description>Commercially marketed, silicone hydrogel, spherical, soft contact lens</description>
        </group>
        <group group_id="E2">
          <title>Lotrafilcon A</title>
          <description>Investigational, silicone hydrogel, spherical, soft contact lens</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Priya Janakiraman, OD, FAAO / Head, Global Clinical Affairs</name_or_title>
      <organization>CIBA VISION</organization>
      <phone>1-800-241-7629</phone>
      <email>priya.janakiraman@cibavision.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

